{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:46:26Z","timestamp":1790178386361,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012156","name":"Shenzen Municipal Technical Project","doi-asserted-by":"publisher","award":["KCXFZ20201221173213036"],"award-info":[{"award-number":["KCXFZ20201221173213036"]}],"id":[{"id":"10.13039\/501100012156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Project of Guangdong Key Laboratory of Biomedical Information Detection and Ultrasound Imaging","award":["SZD202207"],"award-info":[{"award-number":["SZD202207"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["No.SZSN202311007"],"award-info":[{"award-number":["No.SZSN202311007"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen High-level Hospital Construction Fund and Key clinical research project of Shenzhen Second People's Hospital","award":["No.20243357015"],"award-info":[{"award-number":["No.20243357015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although blood-based biomarkers can be used to detect early Alzheimer\u2019s disease (AD), population differences affect their clinical value in early diagnosis of the disease spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To examine the potential of plasma biomarkers to detect different stages along the AD continuum in a Chinese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We enrolled 113 adults from the Shenzhen community (53 cognitively unimpaired [CU], 45 with mild cognitive impairment [MCI], and 15 with AD). We used the single-molecule array technique to detect the levels of glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and phosphorylated-tau181 (p-tau181), and performed\n                      <jats:italic>APOE<\/jats:italic>\n                      genotyping. We assessed the association between plasma biomarkers and cognitive scores, and used receiver operating characteristic curves to measure performance for early AD diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The plasma GFAP, NfL, and p-tau181 levels increased significantly in AD and were slightly higher in MCI than in CU (GFAP\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.811, NfL\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.909, p-tau181\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.696). The plasma GFAP and p-tau181 levels negatively correlated with cognitive scores. Blood markers demonstrated higher performance in identifying AD than CU or MCI. Plasma p-tau181 displayed the highest diagnostic value for AD. Predictions of cognitive impairment were more robust when blood markers were combined with clinical indicators for AD (age, sex, body mass index, years of education, and\n                      <jats:italic>APOE \u03b54<\/jats:italic>\n                      carrier status).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The expression of plasma GFAP, NfL, and p-tau181 increased in the AD continuum. Importantly, plasma p-tau181 could identify individuals with AD from the general population, with superior predictive performance when combined with age or sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma biomarkers are useful screening indicators for early AD in Chinese adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40520-025-03001-y","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T01:12:34Z","timestamp":1743210754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma GFAP, NfL, and p-tau181 levels as early biomarkers of dementia in Chinese adults: Shenzhen community cohort study"],"prefix":"10.1007","volume":"37","author":[{"given":"Chunhua","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"3001_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"3001_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M et al (2021) Alzheimer\u2019s disease. Lancet 397:1577\u20131590. https:\/\/doi.org\/10.1016\/S0140-6736(20)32205-4","journal-title":"Lancet"},{"key":"3001_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3389\/fpsyt.2018.00671","volume":"9","author":"L Lin","year":"2018","unstructured":"Lin L, Xing G, Han Y (2018) Advances in resting state neuroimaging of mild cognitive impairment. Front Psychiatry 9:671. https:\/\/doi.org\/10.3389\/fpsyt.2018.00671","journal-title":"Front Psychiatry"},{"key":"3001_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk I, Thijssen EH et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21:66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6","journal-title":"Lancet Neurol"},{"key":"3001_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/arclin\/acae019","volume":"39","author":"HE Dark","year":"2024","unstructured":"Dark HE, Duggan MR, Walker KA (2024) Plasma biomarkers for Alzheimer\u2019s and related dementias: A review and outlook for clinical neuropsychology. Arch Clin Neuropsychol 39:313\u2013324. https:\/\/doi.org\/10.1093\/arclin\/acae019","journal-title":"Arch Clin Neuropsychol"},{"key":"3001_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molmed.2018.11.006","volume":"25","author":"SF Carter","year":"2019","unstructured":"Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER (2019) Astrocyte biomarkers in Alzheimer\u2019s disease. Trends Mol Med 25:77\u201395. https:\/\/doi.org\/10.1016\/j.molmed.2018.11.006","journal-title":"Trends Mol Med"},{"key":"3001_CR7","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD et al (2023) Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: A cross\u2010sectional and longitudinal study in the AIBL cohort. Alzheimers Dement 19:1117\u20131134. https:\/\/doi.org\/10.1002\/alz.12724","journal-title":"Alzheimers Dement"},{"key":"3001_CR8","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro C, Benkert P, Disanto G et al (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141:2382\u20132391. https:\/\/doi.org\/10.1093\/brain\/awy154","journal-title":"Brain"},{"key":"3001_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and Meta-analysis. JAMA Neurol 76:1035\u20131048. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1534","journal-title":"JAMA Neurol"},{"key":"3001_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cells12091309","volume":"12","author":"KY Kim","year":"2023","unstructured":"Kim KY, Shin KY, Chang KA (2023) GFAP as a potential biomarker for Alzheimer\u2019s disease: A systematic review and Meta-Analysis. Cells 12:1309. https:\/\/doi.org\/10.3390\/cells12091309","journal-title":"Cells"},{"key":"3001_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S et al (2020) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26:379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"key":"3001_CR12","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL et al (2021) Comparison of plasma phosphorylated Tau species with amyloid and Tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol 78:1108\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2293","journal-title":"JAMA Neurol"},{"key":"3001_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S et al (2023) Association of phosphorylated Tau biomarkers with amyloid positron emission tomography vs Tau positron emission tomography. JAMA Neurol 80:188\u2013199. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485","journal-title":"JAMA Neurol"},{"key":"3001_CR14","doi-asserted-by":"publisher","first-page":"1375302","DOI":"10.3389\/fendo.2024.1375302","volume":"15","author":"A Ingannato","year":"2024","unstructured":"Ingannato A, Bagnoli S, Mazzeo S et al (2024) Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia. Front Endocrinol (Lausanne) 15:1375302. https:\/\/doi.org\/10.3389\/fendo.2024.1375302","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3001_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/clinchem\/hvad018","volume":"69","author":"X Shen","year":"2023","unstructured":"Shen X, Huang S, Cui M et al (2023) Plasma glial fibrillary acidic protein in the alzheimer disease continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression. Clin Chem 69:411\u2013421. https:\/\/doi.org\/10.1093\/clinchem\/hvad018","journal-title":"Clin Chem"},{"key":"3001_CR16","doi-asserted-by":"publisher","first-page":"111821","DOI":"10.1016\/j.mad.2023.111821","volume":"212","author":"A Nicoletti","year":"2023","unstructured":"Nicoletti A, Baschi R, Cicero CE et al (2023) Sex and gender differences in Alzheimer\u2019s disease, Parkinson\u2019s disease, and amyotrophic lateral sclerosis: A narrative review. Mech Ageing Dev 212:111821. https:\/\/doi.org\/10.1016\/j.mad.2023.111821","journal-title":"Mech Ageing Dev"},{"key":"3001_CR17","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1038\/s41380-022-01604-9","volume":"27","author":"YT Deng","year":"2022","unstructured":"Deng YT, Li YZ, Huang SY et al (2022) Association of life course adiposity with risk of incident dementia: a prospective cohort study of 322,336 participants. Mol Psychiatry 27:3385\u20133395. https:\/\/doi.org\/10.1038\/s41380-022-01604-9","journal-title":"Mol Psychiatry"},{"key":"3001_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S1474-4422(18)30053-X","volume":"17","author":"SJ van der Lee","year":"2018","unstructured":"van der Lee SJ, Wolters FJ, Ikram MK et al (2018) The effect of APOE and other common genetic variants on the onset of Alzheimer\u2019s disease and dementia: a community-based cohort study. Lancet Neurol 17:434\u2013444. https:\/\/doi.org\/10.1016\/S1474-4422(18)30053-X","journal-title":"Lancet Neurol"},{"key":"3001_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","volume":"51","author":"IE Jansen","year":"2019","unstructured":"Jansen IE, Savage JE, Watanabe K et al (2019) Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat Genet 51:404\u2013413. https:\/\/doi.org\/10.1038\/s41588-018-0311-9","journal-title":"Nat Genet"},{"key":"3001_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk I, den Dulk B et al (2021) Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther 13:198. https:\/\/doi.org\/10.1186\/s13195-021-00939-9","journal-title":"Alzheimers Res Ther"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03001-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-025-03001-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-03001-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:46:55Z","timestamp":1743986815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-025-03001-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3001"],"URL":"https:\/\/doi.org\/10.1007\/s40520-025-03001-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5282562\/v1","asserted-by":"object"}]},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to update the typo in the author name from Xueqing Yan to  Xueqin Yan in the author contribution section.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Clinical Research Ethics Committee of the Second People\u2019s Hospital of Shenzhen (NO:20211013001) approved this study. The participants provided written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}